Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,666
archived clinical trials in
Hospital

Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated:  11/13/2015
University of Nebraska
mi
from
Omaha, NE
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated: 11/13/2015
University of Nebraska
mi
from
Omaha, NE
Click here to add this to my saved trials
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated:  11/13/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated: 11/13/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated:  11/13/2015
Duke Univ Med Ctr
mi
from
Durham, NC
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated: 11/13/2015
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated:  11/13/2015
Wake Forest Medical Center
mi
from
Winston Salem, NC
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated: 11/13/2015
Wake Forest Medical Center
mi
from
Winston Salem, NC
Click here to add this to my saved trials
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated:  11/13/2015
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated: 11/13/2015
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated:  11/13/2015
University of Pittsburg
mi
from
Pittsburg, PA
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated: 11/13/2015
University of Pittsburg
mi
from
Pittsburg, PA
Click here to add this to my saved trials
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated:  11/13/2015
Vanderbilt Medical Center
mi
from
Nashville, TN
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
Status: Enrolling
Updated: 11/13/2015
Vanderbilt Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Skilled Motor Training and tDCS to Improve Leg Function After Spinal Cord Injury
Skilled Motor Training and tDCS to Improve Leg Function After Spinal Cord Injury
Status: Enrolling
Updated:  11/13/2015
The Miami Project to Cure Paralysis
mi
from
Miami, FL
Skilled Motor Training and tDCS to Improve Leg Function After Spinal Cord Injury
Skilled Motor Training and tDCS to Improve Leg Function After Spinal Cord Injury
Status: Enrolling
Updated: 11/13/2015
The Miami Project to Cure Paralysis
mi
from
Miami, FL
Click here to add this to my saved trials
Single Dose Enteral Tranexamic Acid in Critically Ill Patients
Single Dose Enteral Tranexamic Acid for the Reduction of Morbidity in Hospitalized Critically Ill Patients
Status: Enrolling
Updated:  11/16/2015
Va San Diego Health Care System
mi
from
San Diego, CA
Single Dose Enteral Tranexamic Acid in Critically Ill Patients
Single Dose Enteral Tranexamic Acid for the Reduction of Morbidity in Hospitalized Critically Ill Patients
Status: Enrolling
Updated: 11/16/2015
Va San Diego Health Care System
mi
from
San Diego, CA
Click here to add this to my saved trials
Study of an Electronic Health Record-embedded Severe Sepsis Early Warning Alert
Single-blind Randomized Trial of a Commercially Sold Electronic Health Record Based Severe Sepsis Early Warning Best Practice Alert.
Status: Enrolling
Updated:  11/16/2015
Stanford Hospital
mi
from
Stanford, CA
Study of an Electronic Health Record-embedded Severe Sepsis Early Warning Alert
Single-blind Randomized Trial of a Commercially Sold Electronic Health Record Based Severe Sepsis Early Warning Best Practice Alert.
Status: Enrolling
Updated: 11/16/2015
Stanford Hospital
mi
from
Stanford, CA
Click here to add this to my saved trials
An Evaluation of a Cytomegalovirus (CMV) Vaccine (ASP0113) in CMV-Seropositive and CMV-Seronegative Healthy Subjects and CMV-Seronegative Dialysis Patients
A Phase 1, Single-Blind, Parallel-Group, Pharmacokinetic and Immunogenicity Study With ASP0113 in CMV-Seropositive and CMV-Seronegative Healthy Subjects and CMV-Seronegative Dialysis Patients
Status: Enrolling
Updated:  11/18/2015
Site US00112 American Institute of Research
mi
from
Los Angeles, CA
An Evaluation of a Cytomegalovirus (CMV) Vaccine (ASP0113) in CMV-Seropositive and CMV-Seronegative Healthy Subjects and CMV-Seronegative Dialysis Patients
A Phase 1, Single-Blind, Parallel-Group, Pharmacokinetic and Immunogenicity Study With ASP0113 in CMV-Seropositive and CMV-Seronegative Healthy Subjects and CMV-Seronegative Dialysis Patients
Status: Enrolling
Updated: 11/18/2015
Site US00112 American Institute of Research
mi
from
Los Angeles, CA
Click here to add this to my saved trials
An Evaluation of a Cytomegalovirus (CMV) Vaccine (ASP0113) in CMV-Seropositive and CMV-Seronegative Healthy Subjects and CMV-Seronegative Dialysis Patients
A Phase 1, Single-Blind, Parallel-Group, Pharmacokinetic and Immunogenicity Study With ASP0113 in CMV-Seropositive and CMV-Seronegative Healthy Subjects and CMV-Seronegative Dialysis Patients
Status: Enrolling
Updated:  11/18/2015
Site US10003 Orlando Clinical Research Center
mi
from
Orlando, FL
An Evaluation of a Cytomegalovirus (CMV) Vaccine (ASP0113) in CMV-Seropositive and CMV-Seronegative Healthy Subjects and CMV-Seronegative Dialysis Patients
A Phase 1, Single-Blind, Parallel-Group, Pharmacokinetic and Immunogenicity Study With ASP0113 in CMV-Seropositive and CMV-Seronegative Healthy Subjects and CMV-Seronegative Dialysis Patients
Status: Enrolling
Updated: 11/18/2015
Site US10003 Orlando Clinical Research Center
mi
from
Orlando, FL
Click here to add this to my saved trials
An Evaluation of a Cytomegalovirus (CMV) Vaccine (ASP0113) in CMV-Seropositive and CMV-Seronegative Healthy Subjects and CMV-Seronegative Dialysis Patients
A Phase 1, Single-Blind, Parallel-Group, Pharmacokinetic and Immunogenicity Study With ASP0113 in CMV-Seropositive and CMV-Seronegative Healthy Subjects and CMV-Seronegative Dialysis Patients
Status: Enrolling
Updated:  11/18/2015
Site US10001 PAREXEL
mi
from
Baltimore, MD
An Evaluation of a Cytomegalovirus (CMV) Vaccine (ASP0113) in CMV-Seropositive and CMV-Seronegative Healthy Subjects and CMV-Seronegative Dialysis Patients
A Phase 1, Single-Blind, Parallel-Group, Pharmacokinetic and Immunogenicity Study With ASP0113 in CMV-Seropositive and CMV-Seronegative Healthy Subjects and CMV-Seronegative Dialysis Patients
Status: Enrolling
Updated: 11/18/2015
Site US10001 PAREXEL
mi
from
Baltimore, MD
Click here to add this to my saved trials
An Evaluation of a Cytomegalovirus (CMV) Vaccine (ASP0113) in CMV-Seropositive and CMV-Seronegative Healthy Subjects and CMV-Seronegative Dialysis Patients
A Phase 1, Single-Blind, Parallel-Group, Pharmacokinetic and Immunogenicity Study With ASP0113 in CMV-Seropositive and CMV-Seronegative Healthy Subjects and CMV-Seronegative Dialysis Patients
Status: Enrolling
Updated:  11/18/2015
Site US10004 Southwest Houston Research
mi
from
Houston, TX
An Evaluation of a Cytomegalovirus (CMV) Vaccine (ASP0113) in CMV-Seropositive and CMV-Seronegative Healthy Subjects and CMV-Seronegative Dialysis Patients
A Phase 1, Single-Blind, Parallel-Group, Pharmacokinetic and Immunogenicity Study With ASP0113 in CMV-Seropositive and CMV-Seronegative Healthy Subjects and CMV-Seronegative Dialysis Patients
Status: Enrolling
Updated: 11/18/2015
Site US10004 Southwest Houston Research
mi
from
Houston, TX
Click here to add this to my saved trials
Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates
A Multicenter, Randomized, Open-Label, Controlled Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Preterm Neonates 29 to 34 Weeks PMA: Dose Escalation and Study Extension
Status: Enrolling
Updated:  11/19/2015
University of Alabama at Birmingham
mi
from
Birmingham, AL
Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates
A Multicenter, Randomized, Open-Label, Controlled Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Preterm Neonates 29 to 34 Weeks PMA: Dose Escalation and Study Extension
Status: Enrolling
Updated: 11/19/2015
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates
A Multicenter, Randomized, Open-Label, Controlled Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Preterm Neonates 29 to 34 Weeks PMA: Dose Escalation and Study Extension
Status: Enrolling
Updated:  11/19/2015
Arkansas Children's Hospital
mi
from
Little Rock, AR
Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates
A Multicenter, Randomized, Open-Label, Controlled Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Preterm Neonates 29 to 34 Weeks PMA: Dose Escalation and Study Extension
Status: Enrolling
Updated: 11/19/2015
Arkansas Children's Hospital
mi
from
Little Rock, AR
Click here to add this to my saved trials
Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates
A Multicenter, Randomized, Open-Label, Controlled Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Preterm Neonates 29 to 34 Weeks PMA: Dose Escalation and Study Extension
Status: Enrolling
Updated:  11/19/2015
Loma Linda University Medical Center
mi
from
Loma Linda, CA
Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates
A Multicenter, Randomized, Open-Label, Controlled Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Preterm Neonates 29 to 34 Weeks PMA: Dose Escalation and Study Extension
Status: Enrolling
Updated: 11/19/2015
Loma Linda University Medical Center
mi
from
Loma Linda, CA
Click here to add this to my saved trials
Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates
A Multicenter, Randomized, Open-Label, Controlled Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Preterm Neonates 29 to 34 Weeks PMA: Dose Escalation and Study Extension
Status: Enrolling
Updated:  11/19/2015
Sharp Mary Birch Hospital for Women and Newborns
mi
from
San Diego, CA
Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates
A Multicenter, Randomized, Open-Label, Controlled Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Preterm Neonates 29 to 34 Weeks PMA: Dose Escalation and Study Extension
Status: Enrolling
Updated: 11/19/2015
Sharp Mary Birch Hospital for Women and Newborns
mi
from
San Diego, CA
Click here to add this to my saved trials
Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates
A Multicenter, Randomized, Open-Label, Controlled Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Preterm Neonates 29 to 34 Weeks PMA: Dose Escalation and Study Extension
Status: Enrolling
Updated:  11/19/2015
Christiana Care Health System
mi
from
Newark, DE
Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates
A Multicenter, Randomized, Open-Label, Controlled Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Preterm Neonates 29 to 34 Weeks PMA: Dose Escalation and Study Extension
Status: Enrolling
Updated: 11/19/2015
Christiana Care Health System
mi
from
Newark, DE
Click here to add this to my saved trials
Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates
A Multicenter, Randomized, Open-Label, Controlled Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Preterm Neonates 29 to 34 Weeks PMA: Dose Escalation and Study Extension
Status: Enrolling
Updated:  11/19/2015
University of Miami
mi
from
Miami, FL
Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates
A Multicenter, Randomized, Open-Label, Controlled Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Preterm Neonates 29 to 34 Weeks PMA: Dose Escalation and Study Extension
Status: Enrolling
Updated: 11/19/2015
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates
A Multicenter, Randomized, Open-Label, Controlled Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Preterm Neonates 29 to 34 Weeks PMA: Dose Escalation and Study Extension
Status: Enrolling
Updated:  11/19/2015
Riley Hospital for Children at IU Health
mi
from
Indianapolis, IN
Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates
A Multicenter, Randomized, Open-Label, Controlled Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Preterm Neonates 29 to 34 Weeks PMA: Dose Escalation and Study Extension
Status: Enrolling
Updated: 11/19/2015
Riley Hospital for Children at IU Health
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates
A Multicenter, Randomized, Open-Label, Controlled Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Preterm Neonates 29 to 34 Weeks PMA: Dose Escalation and Study Extension
Status: Enrolling
Updated:  11/19/2015
University of Louisville
mi
from
Louisville, KY
Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates
A Multicenter, Randomized, Open-Label, Controlled Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Preterm Neonates 29 to 34 Weeks PMA: Dose Escalation and Study Extension
Status: Enrolling
Updated: 11/19/2015
University of Louisville
mi
from
Louisville, KY
Click here to add this to my saved trials
Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates
A Multicenter, Randomized, Open-Label, Controlled Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Preterm Neonates 29 to 34 Weeks PMA: Dose Escalation and Study Extension
Status: Enrolling
Updated:  11/19/2015
Mid Atlantic Neonatology Associates
mi
from
Morristown, NJ
Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates
A Multicenter, Randomized, Open-Label, Controlled Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Preterm Neonates 29 to 34 Weeks PMA: Dose Escalation and Study Extension
Status: Enrolling
Updated: 11/19/2015
Mid Atlantic Neonatology Associates
mi
from
Morristown, NJ
Click here to add this to my saved trials
Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates
A Multicenter, Randomized, Open-Label, Controlled Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Preterm Neonates 29 to 34 Weeks PMA: Dose Escalation and Study Extension
Status: Enrolling
Updated:  11/19/2015
Duke Univ Med Ctr
mi
from
Durham, NC
Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates
A Multicenter, Randomized, Open-Label, Controlled Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Preterm Neonates 29 to 34 Weeks PMA: Dose Escalation and Study Extension
Status: Enrolling
Updated: 11/19/2015
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates
A Multicenter, Randomized, Open-Label, Controlled Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Preterm Neonates 29 to 34 Weeks PMA: Dose Escalation and Study Extension
Status: Enrolling
Updated:  11/19/2015
Providence St. Vincent Medical Center
mi
from
Portland, OR
Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates
A Multicenter, Randomized, Open-Label, Controlled Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Preterm Neonates 29 to 34 Weeks PMA: Dose Escalation and Study Extension
Status: Enrolling
Updated: 11/19/2015
Providence St. Vincent Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access
A Phase 2, Single-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of SRM003 (Vascugel®) in Improving the Rate of Arteriovenous Fistula Maturation and Use in Subjects Undergoing Surgery for Creation of an Arteriovenous Fistula for Hemodialysis Access
Status: Enrolling
Updated:  11/20/2015
AKDHC Medical Research Services, LLC
mi
from
Phoenix, AZ
An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access
A Phase 2, Single-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of SRM003 (Vascugel®) in Improving the Rate of Arteriovenous Fistula Maturation and Use in Subjects Undergoing Surgery for Creation of an Arteriovenous Fistula for Hemodialysis Access
Status: Enrolling
Updated: 11/20/2015
AKDHC Medical Research Services, LLC
mi
from
Phoenix, AZ
Click here to add this to my saved trials
An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access
A Phase 2, Single-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of SRM003 (Vascugel®) in Improving the Rate of Arteriovenous Fistula Maturation and Use in Subjects Undergoing Surgery for Creation of an Arteriovenous Fistula for Hemodialysis Access
Status: Enrolling
Updated:  11/20/2015
Tucson Vascular Consultants
mi
from
Tucson, AZ
An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access
A Phase 2, Single-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of SRM003 (Vascugel®) in Improving the Rate of Arteriovenous Fistula Maturation and Use in Subjects Undergoing Surgery for Creation of an Arteriovenous Fistula for Hemodialysis Access
Status: Enrolling
Updated: 11/20/2015
Tucson Vascular Consultants
mi
from
Tucson, AZ
Click here to add this to my saved trials
An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access
A Phase 2, Single-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of SRM003 (Vascugel®) in Improving the Rate of Arteriovenous Fistula Maturation and Use in Subjects Undergoing Surgery for Creation of an Arteriovenous Fistula for Hemodialysis Access
Status: Enrolling
Updated:  11/20/2015
Ladenheim Dialysis Access Center
mi
from
Fresno, CA
An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access
A Phase 2, Single-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of SRM003 (Vascugel®) in Improving the Rate of Arteriovenous Fistula Maturation and Use in Subjects Undergoing Surgery for Creation of an Arteriovenous Fistula for Hemodialysis Access
Status: Enrolling
Updated: 11/20/2015
Ladenheim Dialysis Access Center
mi
from
Fresno, CA
Click here to add this to my saved trials
An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access
A Phase 2, Single-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of SRM003 (Vascugel®) in Improving the Rate of Arteriovenous Fistula Maturation and Use in Subjects Undergoing Surgery for Creation of an Arteriovenous Fistula for Hemodialysis Access
Status: Enrolling
Updated:  11/20/2015
California Institute of Renal Research
mi
from
La Mesa, CA
An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access
A Phase 2, Single-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of SRM003 (Vascugel®) in Improving the Rate of Arteriovenous Fistula Maturation and Use in Subjects Undergoing Surgery for Creation of an Arteriovenous Fistula for Hemodialysis Access
Status: Enrolling
Updated: 11/20/2015
California Institute of Renal Research
mi
from
La Mesa, CA
Click here to add this to my saved trials
An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access
A Phase 2, Single-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of SRM003 (Vascugel®) in Improving the Rate of Arteriovenous Fistula Maturation and Use in Subjects Undergoing Surgery for Creation of an Arteriovenous Fistula for Hemodialysis Access
Status: Enrolling
Updated:  11/20/2015
VA Long Beach Health Care System Pharmacy
mi
from
Long Beach, CA
An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access
A Phase 2, Single-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of SRM003 (Vascugel®) in Improving the Rate of Arteriovenous Fistula Maturation and Use in Subjects Undergoing Surgery for Creation of an Arteriovenous Fistula for Hemodialysis Access
Status: Enrolling
Updated: 11/20/2015
VA Long Beach Health Care System Pharmacy
mi
from
Long Beach, CA
Click here to add this to my saved trials
An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access
A Phase 2, Single-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of SRM003 (Vascugel®) in Improving the Rate of Arteriovenous Fistula Maturation and Use in Subjects Undergoing Surgery for Creation of an Arteriovenous Fistula for Hemodialysis Access
Status: Enrolling
Updated:  11/20/2015
The Regents University of California Los Angeles
mi
from
Los Angeles, CA
An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access
A Phase 2, Single-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of SRM003 (Vascugel®) in Improving the Rate of Arteriovenous Fistula Maturation and Use in Subjects Undergoing Surgery for Creation of an Arteriovenous Fistula for Hemodialysis Access
Status: Enrolling
Updated: 11/20/2015
The Regents University of California Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access
A Phase 2, Single-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of SRM003 (Vascugel®) in Improving the Rate of Arteriovenous Fistula Maturation and Use in Subjects Undergoing Surgery for Creation of an Arteriovenous Fistula for Hemodialysis Access
Status: Enrolling
Updated:  11/20/2015
California Institute of Renal Research
mi
from
San Diego, CA
An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access
A Phase 2, Single-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of SRM003 (Vascugel®) in Improving the Rate of Arteriovenous Fistula Maturation and Use in Subjects Undergoing Surgery for Creation of an Arteriovenous Fistula for Hemodialysis Access
Status: Enrolling
Updated: 11/20/2015
California Institute of Renal Research
mi
from
San Diego, CA
Click here to add this to my saved trials
An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access
A Phase 2, Single-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of SRM003 (Vascugel®) in Improving the Rate of Arteriovenous Fistula Maturation and Use in Subjects Undergoing Surgery for Creation of an Arteriovenous Fistula for Hemodialysis Access
Status: Enrolling
Updated:  11/20/2015
University of Colorado Denver
mi
from
Aurora, CO
An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access
A Phase 2, Single-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of SRM003 (Vascugel®) in Improving the Rate of Arteriovenous Fistula Maturation and Use in Subjects Undergoing Surgery for Creation of an Arteriovenous Fistula for Hemodialysis Access
Status: Enrolling
Updated: 11/20/2015
University of Colorado Denver
mi
from
Aurora, CO
Click here to add this to my saved trials
An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access
A Phase 2, Single-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of SRM003 (Vascugel®) in Improving the Rate of Arteriovenous Fistula Maturation and Use in Subjects Undergoing Surgery for Creation of an Arteriovenous Fistula for Hemodialysis Access
Status: Enrolling
Updated:  11/20/2015
Yale University School of Medicine
mi
from
New Haven, CT
An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access
A Phase 2, Single-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of SRM003 (Vascugel®) in Improving the Rate of Arteriovenous Fistula Maturation and Use in Subjects Undergoing Surgery for Creation of an Arteriovenous Fistula for Hemodialysis Access
Status: Enrolling
Updated: 11/20/2015
Yale University School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access
A Phase 2, Single-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of SRM003 (Vascugel®) in Improving the Rate of Arteriovenous Fistula Maturation and Use in Subjects Undergoing Surgery for Creation of an Arteriovenous Fistula for Hemodialysis Access
Status: Enrolling
Updated:  11/20/2015
Tampa General Hospital
mi
from
Tampa, FL
An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access
A Phase 2, Single-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of SRM003 (Vascugel®) in Improving the Rate of Arteriovenous Fistula Maturation and Use in Subjects Undergoing Surgery for Creation of an Arteriovenous Fistula for Hemodialysis Access
Status: Enrolling
Updated: 11/20/2015
Tampa General Hospital
mi
from
Tampa, FL
Click here to add this to my saved trials
An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access
A Phase 2, Single-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of SRM003 (Vascugel®) in Improving the Rate of Arteriovenous Fistula Maturation and Use in Subjects Undergoing Surgery for Creation of an Arteriovenous Fistula for Hemodialysis Access
Status: Enrolling
Updated:  11/20/2015
Augusta University
mi
from
Augusta, GA
An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access
A Phase 2, Single-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of SRM003 (Vascugel®) in Improving the Rate of Arteriovenous Fistula Maturation and Use in Subjects Undergoing Surgery for Creation of an Arteriovenous Fistula for Hemodialysis Access
Status: Enrolling
Updated: 11/20/2015
Augusta University
mi
from
Augusta, GA
Click here to add this to my saved trials
An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access
A Phase 2, Single-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of SRM003 (Vascugel®) in Improving the Rate of Arteriovenous Fistula Maturation and Use in Subjects Undergoing Surgery for Creation of an Arteriovenous Fistula for Hemodialysis Access
Status: Enrolling
Updated:  11/20/2015
Illinois Kidney Disease & Hypertension Center
mi
from
Peoria, IL
An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access
A Phase 2, Single-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of SRM003 (Vascugel®) in Improving the Rate of Arteriovenous Fistula Maturation and Use in Subjects Undergoing Surgery for Creation of an Arteriovenous Fistula for Hemodialysis Access
Status: Enrolling
Updated: 11/20/2015
Illinois Kidney Disease & Hypertension Center
mi
from
Peoria, IL
Click here to add this to my saved trials
An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access
A Phase 2, Single-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of SRM003 (Vascugel®) in Improving the Rate of Arteriovenous Fistula Maturation and Use in Subjects Undergoing Surgery for Creation of an Arteriovenous Fistula for Hemodialysis Access
Status: Enrolling
Updated:  11/20/2015
University of Louisville
mi
from
Louisville, KY
An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access
A Phase 2, Single-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of SRM003 (Vascugel®) in Improving the Rate of Arteriovenous Fistula Maturation and Use in Subjects Undergoing Surgery for Creation of an Arteriovenous Fistula for Hemodialysis Access
Status: Enrolling
Updated: 11/20/2015
University of Louisville
mi
from
Louisville, KY
Click here to add this to my saved trials
An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access
A Phase 2, Single-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of SRM003 (Vascugel®) in Improving the Rate of Arteriovenous Fistula Maturation and Use in Subjects Undergoing Surgery for Creation of an Arteriovenous Fistula for Hemodialysis Access
Status: Enrolling
Updated:  11/20/2015
Ochsner Baptist Medical Center, Clinical Trials Unit
mi
from
New Orleans, LA
An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access
A Phase 2, Single-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of SRM003 (Vascugel®) in Improving the Rate of Arteriovenous Fistula Maturation and Use in Subjects Undergoing Surgery for Creation of an Arteriovenous Fistula for Hemodialysis Access
Status: Enrolling
Updated: 11/20/2015
Ochsner Baptist Medical Center, Clinical Trials Unit
mi
from
New Orleans, LA
Click here to add this to my saved trials
An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access
A Phase 2, Single-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of SRM003 (Vascugel®) in Improving the Rate of Arteriovenous Fistula Maturation and Use in Subjects Undergoing Surgery for Creation of an Arteriovenous Fistula for Hemodialysis Access
Status: Enrolling
Updated:  11/20/2015
Louisiana State University Health Science Center-Shreveport
mi
from
Shreveport, LA
An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access
A Phase 2, Single-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of SRM003 (Vascugel®) in Improving the Rate of Arteriovenous Fistula Maturation and Use in Subjects Undergoing Surgery for Creation of an Arteriovenous Fistula for Hemodialysis Access
Status: Enrolling
Updated: 11/20/2015
Louisiana State University Health Science Center-Shreveport
mi
from
Shreveport, LA
Click here to add this to my saved trials
An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access
A Phase 2, Single-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of SRM003 (Vascugel®) in Improving the Rate of Arteriovenous Fistula Maturation and Use in Subjects Undergoing Surgery for Creation of an Arteriovenous Fistula for Hemodialysis Access
Status: Enrolling
Updated:  11/20/2015
Baystate Medical Center Pharmacy
mi
from
Springfield, MA
An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access
A Phase 2, Single-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of SRM003 (Vascugel®) in Improving the Rate of Arteriovenous Fistula Maturation and Use in Subjects Undergoing Surgery for Creation of an Arteriovenous Fistula for Hemodialysis Access
Status: Enrolling
Updated: 11/20/2015
Baystate Medical Center Pharmacy
mi
from
Springfield, MA
Click here to add this to my saved trials
An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access
A Phase 2, Single-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of SRM003 (Vascugel®) in Improving the Rate of Arteriovenous Fistula Maturation and Use in Subjects Undergoing Surgery for Creation of an Arteriovenous Fistula for Hemodialysis Access
Status: Enrolling
Updated:  11/20/2015
Renaissance Renal Research Institute, LLC
mi
from
Detroit, MI
An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access
A Phase 2, Single-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of SRM003 (Vascugel®) in Improving the Rate of Arteriovenous Fistula Maturation and Use in Subjects Undergoing Surgery for Creation of an Arteriovenous Fistula for Hemodialysis Access
Status: Enrolling
Updated: 11/20/2015
Renaissance Renal Research Institute, LLC
mi
from
Detroit, MI
Click here to add this to my saved trials
An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access
A Phase 2, Single-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of SRM003 (Vascugel®) in Improving the Rate of Arteriovenous Fistula Maturation and Use in Subjects Undergoing Surgery for Creation of an Arteriovenous Fistula for Hemodialysis Access
Status: Enrolling
Updated:  11/20/2015
Henry Ford Hospital
mi
from
Detroit, MI
An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access
A Phase 2, Single-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of SRM003 (Vascugel®) in Improving the Rate of Arteriovenous Fistula Maturation and Use in Subjects Undergoing Surgery for Creation of an Arteriovenous Fistula for Hemodialysis Access
Status: Enrolling
Updated: 11/20/2015
Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access
A Phase 2, Single-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of SRM003 (Vascugel®) in Improving the Rate of Arteriovenous Fistula Maturation and Use in Subjects Undergoing Surgery for Creation of an Arteriovenous Fistula for Hemodialysis Access
Status: Enrolling
Updated:  11/20/2015
McLaren Northern Michigan Hospital-NISUS Research
mi
from
Petoskey, MI
An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access
A Phase 2, Single-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of SRM003 (Vascugel®) in Improving the Rate of Arteriovenous Fistula Maturation and Use in Subjects Undergoing Surgery for Creation of an Arteriovenous Fistula for Hemodialysis Access
Status: Enrolling
Updated: 11/20/2015
McLaren Northern Michigan Hospital-NISUS Research
mi
from
Petoskey, MI
Click here to add this to my saved trials
An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access
A Phase 2, Single-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of SRM003 (Vascugel®) in Improving the Rate of Arteriovenous Fistula Maturation and Use in Subjects Undergoing Surgery for Creation of an Arteriovenous Fistula for Hemodialysis Access
Status: Enrolling
Updated:  11/20/2015
Providence Hospital, Research Dept.
mi
from
Southfield, MI
An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access
A Phase 2, Single-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of SRM003 (Vascugel®) in Improving the Rate of Arteriovenous Fistula Maturation and Use in Subjects Undergoing Surgery for Creation of an Arteriovenous Fistula for Hemodialysis Access
Status: Enrolling
Updated: 11/20/2015
Providence Hospital, Research Dept.
mi
from
Southfield, MI
Click here to add this to my saved trials
An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access
A Phase 2, Single-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of SRM003 (Vascugel®) in Improving the Rate of Arteriovenous Fistula Maturation and Use in Subjects Undergoing Surgery for Creation of an Arteriovenous Fistula for Hemodialysis Access
Status: Enrolling
Updated:  11/20/2015
Clinical Research Consultants
mi
from
Kansas City, MO
An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access
A Phase 2, Single-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of SRM003 (Vascugel®) in Improving the Rate of Arteriovenous Fistula Maturation and Use in Subjects Undergoing Surgery for Creation of an Arteriovenous Fistula for Hemodialysis Access
Status: Enrolling
Updated: 11/20/2015
Clinical Research Consultants
mi
from
Kansas City, MO
Click here to add this to my saved trials
An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access
A Phase 2, Single-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of SRM003 (Vascugel®) in Improving the Rate of Arteriovenous Fistula Maturation and Use in Subjects Undergoing Surgery for Creation of an Arteriovenous Fistula for Hemodialysis Access
Status: Enrolling
Updated:  11/20/2015
Sierra Nevada Nephrology Consultants
mi
from
Reno, NV
An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access
A Phase 2, Single-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of SRM003 (Vascugel®) in Improving the Rate of Arteriovenous Fistula Maturation and Use in Subjects Undergoing Surgery for Creation of an Arteriovenous Fistula for Hemodialysis Access
Status: Enrolling
Updated: 11/20/2015
Sierra Nevada Nephrology Consultants
mi
from
Reno, NV
Click here to add this to my saved trials
An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access
A Phase 2, Single-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of SRM003 (Vascugel®) in Improving the Rate of Arteriovenous Fistula Maturation and Use in Subjects Undergoing Surgery for Creation of an Arteriovenous Fistula for Hemodialysis Access
Status: Enrolling
Updated:  11/20/2015
Montefiore Medical Center
mi
from
Bronx, NY
An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access
A Phase 2, Single-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of SRM003 (Vascugel®) in Improving the Rate of Arteriovenous Fistula Maturation and Use in Subjects Undergoing Surgery for Creation of an Arteriovenous Fistula for Hemodialysis Access
Status: Enrolling
Updated: 11/20/2015
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access
A Phase 2, Single-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of SRM003 (Vascugel®) in Improving the Rate of Arteriovenous Fistula Maturation and Use in Subjects Undergoing Surgery for Creation of an Arteriovenous Fistula for Hemodialysis Access
Status: Enrolling
Updated:  11/20/2015
United Health Services
mi
from
Johnson City, NY
An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access
A Phase 2, Single-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of SRM003 (Vascugel®) in Improving the Rate of Arteriovenous Fistula Maturation and Use in Subjects Undergoing Surgery for Creation of an Arteriovenous Fistula for Hemodialysis Access
Status: Enrolling
Updated: 11/20/2015
United Health Services
mi
from
Johnson City, NY
Click here to add this to my saved trials
An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access
A Phase 2, Single-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of SRM003 (Vascugel®) in Improving the Rate of Arteriovenous Fistula Maturation and Use in Subjects Undergoing Surgery for Creation of an Arteriovenous Fistula for Hemodialysis Access
Status: Enrolling
Updated:  11/20/2015
Mount Sinai School of Medicine Lab
mi
from
New York, NY
An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access
A Phase 2, Single-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of SRM003 (Vascugel®) in Improving the Rate of Arteriovenous Fistula Maturation and Use in Subjects Undergoing Surgery for Creation of an Arteriovenous Fistula for Hemodialysis Access
Status: Enrolling
Updated: 11/20/2015
Mount Sinai School of Medicine Lab
mi
from
New York, NY
Click here to add this to my saved trials